Fibromun is under clinical development by Philogen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fibromun’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fibromun (L19-TNF alpha monoclonal antibody-cytokine fusion protein) is under development for the treatment of malignant fibrous histiocytoma, myxoid liposarcoma, round cell liposarcoma, pleomorphic liposarcoma, dedifferentiated liposarcoma, liposarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, myxofibrosarcoma intermediate and high-grade, fibrosarcoma, angiosarcoma, alveolar rhabdomyosarcoma, newly diagnosed glioblastoma, soft tissue sarcoma, leiomyosarcoma, malignant glioma, glioma and advanced solid tumors. It is administered through intravenous route as a solution. It is a fully-human vascular targeting immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19). It is developed based on immunocytokine technology. It was also under development for the treatment of colorectal cancer and melanoma in combination with melphalan.
Philogen is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s product portfolio include NidlegyTM, Fibromun, Darleukin, Dodekin, Dekavil and ABBV-022. The company provides dekavil and tetravil and others targeted at the treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. It offers DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. The company is also advancing clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy.
For a complete picture of Fibromun’s drug-specific PTSR and LoA scores, buy the report here.